schedules with meningococcal ACWY vaccine.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Meningococcal (A, C, Y and W-135) conjugate vaccine | |
| INITIATION – Children under 12 months of age Prerequisites (tick boxes where appropriate) | |
| A maximum of three doses (dependant on age at first dose) for patients pre- and post- splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post- solid organ transplant A maximum of three doses (dependant on age at first dose) for close contacts of meningococcal cases of any group A maximum of three doses (dependant on age at first dose) for child who has previously had meningococcal disease of any group A maximum of three doses (dependant on age at first dose) for bone marrow transplant patients A maximum of three doses (dependant on age at first dose) for child pre- and post-immunosuppression* | |
| Note: infants from 6 weeks to less than 6 months of age require a 2+1 so than 12 months of age require a 1+1 schedule. Refer to the Immunisatio | |

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

I confirm that the above details are correct: Signed: Date: